PMA covers the use of the Mynx Control device in in procedures with access sites from 6F to 12F. Mynx Control expands the Cordis portfolio of extravascular closure devices designed to delivery predictable deployment and ease of use.

Features include the company’s Grip Technology, based on hydrophilic, bioinert polyethylene glycol (PEG). This enables the VCD sealant to resorb three times faster than collagen-based sealants. According to a news release, it also provides the quickest time to hemostasis of any venous closure device on the market.